About
GT Biopharma is a biotechnology company developing novel immuno-oncology biopharmaceutical drugs using its proprietary NK cell engager (TriKE) platform technology. By leveraging this innovative approach, GT Biopharma is targeting cancers such as acute myeloid leukemia, myeloid dysplastic syndrome, and multiple solid tumors. Traded on NASDAQ under GTBP, the company is committed to advancing cutting-edge therapies that harness the power of the immune system to fight cancer.
San Francisco